Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration.

The cause of the neurodegenerative process in Parkinson's disease (PD) remains unclear, but evidence suggests that failure of the ubiquitin-proteasome system may play a major role in the pathogenesis of the disease. Iron is believed to be a key contributor to PD pathology by inducing aggregation of alpha-synuclein and by generating oxidative stress. Our present studies have shown that micro-injection of the proteasome inhibitor lactacystin into the substantia nigra (SN) of C57BL/6 mice causes significant loss of dopaminergic cells and induces intracellular inclusion body formation. We have also found that co-injection of the iron chelator desferrioxamine not only attenuates the lactacystin-induced dopamine neuron loss, but also reduces the presence of ubiquitin-positive intracellular inclusions in the SN, whereas use of iron-deficient diet has no such protective effects. These results may support that iron plays a key role in proteasome inhibitor-induced nigral pathology and that reducing iron reactivity may prevent dopaminergic neuron degeneration and reduce abnormal protein aggregation.

[1]  D. Perl,et al.  Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease , 2004, Annals of neurology.

[2]  D. Richardson Novel Chelators for Central Nervous System Disorders That Involve Alterations in the Metabolism of Iron and Other Metal Ions , 2004, Annals of the New York Academy of Sciences.

[3]  J. Trojanowski,et al.  Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.

[4]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[5]  G. Irvine,et al.  Aggregation and neurotoxicity of α-synuclein and related peptides , 2001 .

[6]  T. Arendt,et al.  Effect of advanced glycation endproducts on cell cycle and their relevance for Alzheimer's disease. , 2003, Journal of neural transmission. Supplementum.

[7]  K. Jellinger,et al.  Recent developments in the pathology of Parkinson's disease. , 2002, Journal of neural transmission. Supplementum.

[8]  Kazuhiro Iwai,et al.  Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice , 2001, Nature Genetics.

[9]  C. Olanow,et al.  Proteasome inhibition causes nigral degeneration with inclusion bodies in rats , 2002, Neuroreport.

[10]  T. Sherer,et al.  Ubiquitin–proteasome system and Parkinson's diseases , 2005, Experimental Neurology.

[11]  E. Masliah,et al.  Role of Cytochrome c as a Stimulator of α-Synuclein Aggregation in Lewy Body Disease* , 1999, The Journal of Biological Chemistry.

[12]  H J Gundersen,et al.  The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[13]  E. Hirsch,et al.  Lack of up‐regulation of ferritin is associated with sustained iron regulatory protein‐1 binding activity in the substantia nigra of patients with Parkinson's disease , 2002, Journal of neurochemistry.

[14]  Colin L. Masters,et al.  Neurodegenerative diseases and oxidative stress , 2004, Nature Reviews Drug Discovery.

[15]  J. Connor,et al.  Regional brain iron, ferritin and transferrin concentrations during iron deficiency and iron repletion in developing rats. , 1997, The Journal of nutrition.

[16]  M. Youdim,et al.  Iron and α-synuclein in the substantia nigra of MPTP-treated mice , 2007, Journal of Molecular Neuroscience.

[17]  B. Wolozin,et al.  Book Review: Iron and Parkinson’s Disease , 2002, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[18]  K. Double,et al.  The Relevance of Iron in the Pathogenesis of Parkinson's Disease , 2004, Annals of the New York Academy of Sciences.

[19]  H. Vorum,et al.  Ca2+ Binding to α-Synuclein Regulates Ligand Binding and Oligomerization* , 2001, The Journal of Biological Chemistry.

[20]  V. Uversky,et al.  Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. , 2001, The Journal of biological chemistry.

[21]  A. Siderowf,et al.  Update on Parkinson Disease , 2003, Annals of Internal Medicine.

[22]  C. Olanow,et al.  Ubiquitin–proteasome system and Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[23]  G. Delitala,et al.  A clinical study on the relationship between the pineal gland and the opioid system , 2005, Journal of Neural Transmission.

[24]  K. Jellinger,et al.  The Role of Iron in Neurodegeneration , 1999, Drugs & aging.

[25]  Joseph Jankovic,et al.  Neurodegenerative disease and iron storage in the brain , 2004, Current opinion in neurology.